APOE4 is a major genetic risk factor for Alzheimer's disease (AD), but around 40 % of AD patients lack APOE4. It is unclear how APOE4 affects AD hallmarks, particularly during the prodromal disease stage. We tested 152 prodromal AD patients from the Swedish BioFINDER cohort (44 APOE4-negative and 108 APOE4-positive). APOE4 was not associated with global cognition, memory, or cortical A load, but APOE4-negative prodromal AD patients had more impaired executive function, more rapid progression of global cognition, higher cerebrospinal fluid levels of A peptides and neuronal injury biomarkers, more white matter pathology and other signs of vascular burden, and more cortical atrophy compared to APOE4-positive patients. APOE4 only had minor effects on cortical tau retention, measured by 18F-AV-1451 PET in 39 AD patients (whereof 15 APOE4-negative). We conclude that AD is heterogenic with multiple APOE4-dependent differences, which are present already at the prodromal stage of the disease.
Introduction
The APOE4 allele is a major genetic risk factor for Alzheimer's disease (AD) 1 . APOE4 may facilitate brain accumulation of-amyloid (A), triggering a cascade that leads to spread of tau pathology, synaptic dysfunction, atrophy and cognitive decline 2 . Around 40 % of sporadic AD dementia patients are APOE4-negative 1 . These typically develop dementia at a later age 3 , but APOE4-negativity is also overrepresented among the rare patients with early onset and rapidly progressive AD 4 . Preliminary studies suggest that APOE4-negative AD patients may have less impairment of memory retention but more impairment of executive function 5 , and less hippocampal atrophy and temporal lobe hypometabolism 6 but more frontoparietal atrophy 5 , compared to APOE4-positive AD. However, previous research on APOE4 in AD is limited by several factors. The earliest studies did not include Abiomarker confirmation of AD, which makes it possible that some patients were erroneously diagnosed with AD. Furthermore, most studies focus on the dementia stage of the disease, and data are lacking on APOE4-effects in the prodromal disease stage, which is increasingly important for drug development 7 . Lastly, it is not known if APOE4 affects tau pathology in AD. To clarify the role of APOE4, we studied people with prodromal AD, defined as Apositive MCI (below we use the terms "prodromal AD" and "A-positive MCI" interchangeably). We hypothesized that APOE4-negativity affects the phenotype of prodromal AD, that is its clinical presentation as well as underlying brain changes including structural alterations estimated using magnetic resonance imaging and A and tau accumulation determined in the CSF or measured using PET..
Materials and methods

Subjects
All subjects were recruited from the Swedish 4-centre BioFINDER study (Biomarkers For Identifying Neurodegenerative Disorders Early and Reliably). Inclusion/exclusion criteria have been described previously 8, 9 . We included 273 consecutively recruited MCI patients, who were assessed by physicians with special competence in dementia disorders. The inclusion criteria for MCI were that the patients were referred to the memory clinics due to cognitive impairment, did not fulfill the criteria for dementia, had MMSE 24-30, had MCI per a neuropsychological battery and the assessment of a senior neuropsychologist, were 60-80 years old, and were fluent in Swedish. Patients were excluded if they had cognitive impairment that without doubt could be explained by another condition (other than prodromal dementia), had severe somatic disease, or refused lumbar puncture or neuropsychological investigation.
For the tau PET substudy, we included 39 patients with AD dementia, recruited at the Memory Clinic, Skåne University Hospital. These patients were also assessed by physicians with special competence in dementia disorders, and met the DSM-IIIR criteria for dementia 10 as well as the NINCDS-ADRDA criteria for AD 11 . The exclusion criteria were: 1) significant systemic illness making it difficult to participate and 2) significant alcohol abuse. Sixteen of the patients for the tau PET substudy were also included in the main study population (they had progressed to the dementia stage of AD at the start of the tau PET substudy).
Cognitive measures
We used the mini mental state examination (MMSE) as a measure of general cognition. We used the delayed recall memory test from the Alzheimer's Disease Assessment Scalecognitive subscale (ADAS-cog; list learning, 10 items), and immediate (5 min) and delayed results (20 min) from the Rey Auditory Verbal Learning Test (RAVLT) as measures of memory. We used Trailmaking A (TMT-A), the Symbol digit modalities test, and the A Quick Test of cognitive speed (AQT) 12 as measures of attention and processing speed (also referred to as executive function).
CSF biomarkers
All subjects underwent lumbar CSF sampling, following the Alzheimer's Association Flow Chart 13 . Samples were stored in 1 ml polypropylene tubes at -80°C until analysis. ELISAs were used for analysis of CSF Aβ38, Aβ40, Aβ42, T-tau (ADx/EUROIMMUN AG, Lübeck, Germany), P-tau (INNOTEST, Fujiribio Innogenetics, Ghent, Belgium) and NfL (Nf-light, Uman Diagnostics, Umeå, Sweden). The CSF Aβ42:Aβ40 ratio was used to define Aβpositivity in the MCI patients (cutoff <0.1 indicating positivity) 14 . For the tau PET substudy, we verified Aβ-positivity using CSF Aβ42 (cutoff < 650 ng/L indicating positivity; Aβ40 was not available in this cohort) 8 ). All analyses were performed by board-certified laboratory technicians, who were blinded for clinical data and diagnoses.
F-flutemetamol PET imaging
Brain Aβ was measured using 18 F-flutemetamol PET 15, 16 in 89 A-positive MCI and 71 Anegative MCI patients. PET/CT scanning was conducted at two sites using the same type of scanner, a Philips Gemini TF 16. PET sum images from 90-110 min post injection were generated for the average uptake. MRI results were not used since this does not improve the quantification of 18 F-flutemetamol data 17 . The images were analysed using the NeuroMarQ software provided by GE Healthcare. A volume of interest (VOI) template was applied for 9 bilateral regions (prefrontal, parietal, lateral temporal, medial temporal, sensorimotor, occipital, anterior cingulate and posterior cingulate/precuneus), combined in a global neocortical composite signal 17 . The standardized uptake value ratio (SUVR) was the global composite tracer uptake, normalized for the mean uptake in the cerebellar cortex.
Brain structure T1-weighted imaging was performed on a 3T MR scanner (Siemens Tim Trio 3T, Siemens Medical Solutions, Erlangen, Germany), producing a high resolution anatomical MP-RAGE image (TR=1950 ms TE=3.4 ms, 1 mm isotropic voxels and 178 slices). Cortical reconstruction and volumetric segmentation were performed with the Freesurfer image analysis pipeline v5.3 (http://surfer.nmr.mgh.harvard.edu/). Briefly, the T1-weighted images underwent correction for intensity homogeneity 18 , removal of non-brain tissue 19 , and segmentation into GM and White Matter (WM) with intensity gradient and connectivity among voxels [20] [21] [22] [23] . Cortical modeling allowed parcellation of the cerebral cortex into units with respect to gyral and sulcal structure 24, 25 . Cortical thickness was measured as the distance from the gray/white matter boundary to the corresponding pial surface 21 Reconstructed data sets were visually inspected for accuracy, and segmentation errors were corrected.
White matter lesions
Presence of WML was visually assessed on FLAIR images according to the Fazekas scale 26 , resulting in a total Fazekas score, and according to the age-related white matter changes (ARWMC) scale 27 , resulting in regional as well as total scores. In addition, automated segmentation of WML was performed using the Lesion Segmentation Tool (LST) implemented in SPM8 (http://www.applied-statistics.de/lst.html), that generated a total lesion volume for each individual 28 .
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Tau PET imaging and processing
Tau PET imaging was done with procedures described previously 29 . In brief, 18 F-AV-1451 was synthesized at Skåne University Hospital, Lund 30 and PET scans were performed on a GE Discovery 690 PET scanner (General Electric Medical Systems). Partial Volume Error (PVE) correction was performed using the Geometric Transfer Method (GTM) 31 , and combined with Region Based Voxel-wise (RBV) 32 . FreeSurfer parcellation in MR space of the anatomical scan was applied to processed, coregistered and time-averaged PET images to extract regional uptake values. 18 F-AV-1451 standardized uptake value (SUV) images were based on mean uptake over 80-120 min postinjection normalized to uptake in a GM masked cerebellum reference region. We restricted the tau PET analyses to five a priori defined regions of interest (ROIs). This graded tau pathology from stage I to stage VI depending on involvement of specific brain regions, as described in 33 . In sum, the regions included were tau stage I-II (entorhinal), tau stage III (parahippocampal, fusiform, amygdala), tau stage IV (inferior temporal, middle temporal), tau stage V (posterior cingulate, caudal anterior cingulate, rostral anterior cingulate, precuneus, inferior parietal, superior parietal, insula, supramarginal, lingual, superior temporal, medial orbitofrontal, rostral middle frontal, lateral orbitofrontal, caudal middle frontal, superior frontal, lateral occipital) and tau stage VI (precentral gyrus, postcentral gyrus, paracentral gyrus) regions. The system is largely analogous to the Braak staging approach for tau pathology 34 . For each tau stage region, the signal was calculated as the sum of the volume-adjusted regional 18 F-AV-1451 PET signals.
Statistics
Group differences in demographics and medical history were tested by Mann-Whitney tests and Fisher's exact tests. Effects of APOE4 on continuous outcomes were tested by linear regression models, adjusted for age, sex, education, A-pathology, the interaction between A and APOE4, and, when applicable, intracranial volume. In a sensitivity analysis, we also tested effects with and without adjusting for WML load. Longitudinal effects were tested by linear mixed effects model. All tests were two-sided. Significance was set at p < .05. All statistics were done using R (v. 3.2.3, The R Foundation for Statistical Computing).
Standard Protocol Approvals, Registrations, and Patient Consents
The Regional Ethics Committee in Lund, Sweden, approved the BioFINDER study. All study participants gave written informed consent.
Results
See Table 1 for demographics (demographics for the tau PET substudy are described below).
Among A-negative MCI, there were 1 APOE 22 (1%), 18 APOE23 (15%), 70 APOE 33 (58%), 2 APOE 24 (2%), 27 APOE 34 (23%), and 3 APOE44 (3%) patients, and among A-positive MCI (prodromal AD), there were 3 APOE23 (2%), 41 APOE4-negative prodromal AD had higher prevalence of stroke/TIA and greater use of platelet inhibitors than APOE4-positive prodromal AD (Table 1 ). There were no effects of APOE4 on demographic variables in A-negative MCI.
Cognition and function
APOE4-negative prodromal AD had worse results on tests measuring attention and processing speed, including symbol digit, AQT form, and AQT color & form, and greater overall functional impairment, compared to APOE4-positive prodromal AD (Table 2) , but APOE4 was not associated with differences in global cognition (MMSE) or memory function (ADAS-cog 10 wordlist delayed recall and RAVLT). There were no significant effects of APOE4 in A-negative MCI.
Longitudinal data was available for MMSE (in 252 participants at 1 year, 203 participants at 2 years, 152 participants at 3 years and 79 participants at 4 years). APOE4negative prodromal AD declined 0.65 points more in MMSE per year compared to APOE4positive prodromal AD (P=0.028, Figure 1 ).
A pathology
The regional fibrillary A-load measured by 18 F-flutemetamol PET imaging did not differ by APOE4 in prodromal AD ( Table 2 ). Among A-negative MCI, APOE4-positive patients had slightly greater 18 F-flutemetamol uptake compared to APOE4-negative patients in most tested regions, with significantly higher uptake in the temporal mesial region (P=0.046).
CSF biomarkers
APOE4-negative prodromal AD had higher CSF concentrations of A40, A42, T-tau and NfL compared to APOE4-positive prodromal AD ( Table 2 ). CSF concentrations of A38 and P-tau were also numerically higher but the differences were not significant. In Anegative MCI, APOE4-negative patients had higher CSF A42 than APOE4-positive.
Brain structure APOE4-negative prodromal AD had reduced cortical thickness in widespread temporoparietal and dorsolateral frontal regions compared to APOE4-positive prodromal AD (Figure 2 ). There were no significant effects of APOE4 on cortical thickness in Anegative MCI, or on subcortical structures (data not shown).
White matter lesions
APOE4-negative prodromal AD had more WML, measured both by the total WML load and age-related white matter changes ( Table 2) . APOE4-negative prodromal AD also had lower mean diffusivity and higher fractional anisotropy in white matter tracts (Figure 3 ). There were no effects of APOE4 on WML or diffusivity in white matter tracts among A-negative MCI (not shown).
Post hoc, we asked if the differences in WML could explain the other differences that we found between APOE4-negative and APOE4-positive prodromal AD patients, but adjusting for WML load had only minor effects on the other estimates ( Figure 4 ).
Tau PET
We performed tau PET imaging using the tracer 18 18 F-AV-1451 retention, except for stage VI regions, where APOE4-negative patients had significantly more tau retention ( Figure 5 ).
Discussion
APOE4 has widespread effects on clinical, neurochemical and anatomical endophenotypes in AD. As expected, only a minority (29%) of AD patients lacked the APOE4-allele, but the APOE4-negative patients had more dysexecutive impairment, more rapid progression of cognitive decline, higher CSF concentrations of both A biomarkers and biomarkers of axonal injury, thinner cortices in parietotemporal and frontal brain regions, more white matter pathology, and more disruption of white matter tracts, despite no effects of APOE4 on A pathology and only minor effects on tau pathology. Taken together, these results show a significant heterogeneity among AD patients, where APOE4-negative patients are more likely to have an atypical disease phenotype.
APOE4-negative AD patients had worse results on tests related to attention and processing speed. This was in agreement with previous findings on AD dementia patients 5 .
We also found that APOE4-negative AD had worse overall clinical function, as indicated by a greater FAQ score, although the groups did not differ on memory or overall cognition.
Clinicians should be aware that a dysexecutive cognitive profile may predominate in AD, and that APOE4-negativity may be over-represented among atypical AD patients 35 . Likewise, clinical trial designers should be prepared to meet alternative cognitive trajectories in APOE4-negative AD, since these may affect the power to detect effects of novel therapies, and potentially affect the generalizability of findings from APOE4-postive to -negative subjects.
We also identified several neurochemical associations with APOE 4. We have reported before (partly in the same subjects) that APOE4-negative AD is associated with increased CSF levels of different A peptide species 36 . Hypothetically, people who develop A pathology despite lacking APOE4 may have abnormalities in their A metabolism that contributes to the formation of A pathology. APOE4-negative AD patients also had higher concentrations of CSF T-tau and NfL, which are proteins enriched in cortical axons and myelinated subcortical axons, respectively 37 . AD patients have increased concentrations of both CSF T-tau and NfL 38 , but NfL is even more increased in other dementias 39 . The higher CSF T-tau and NfL concentrations in APOE4-negative AD may indicate a more aggressive and rapidly progressing general axonal degeneration in these patients. This is in agreement with the more rapid decline in MMSE in APOE4-negative AD. A neuropathological study which compared slowly and rapidly progressive AD found that APOE4-negatives were more common in the rapidly progressive group 4 . However, those patients were also quite young, while we did not find any APOE4-dependent age-difference in our AD patients. The theory that APOE4-negative AD patients had more aggressive neurodegeneration was also supported by the pronounced brain atrophy in parietotemporal and dorsolateral frontal cortical regions. Previous studies found that APOE4-negative AD have more frontal and parietal atrophy 5 , while APOE4-positive AD have more temporal or hippocampal atrophy 6, 40, 41 . We did not find any APOE-dependent differences on subcortical structures, including the hippocampi.
Finally, APOE4-negative prodromal AD patients had increased white matter damage and microstructural white matter tract alterations. Together with their dysexecutive cognitive profile, increased CSF NfL concentrations, greater incidence of stroke/TIA and greater use of platelet inhibitors, this indicates that APOE4-negative AD patients had a greater overall vascular burden compared to APOE4-positive patients. However, this was unlikely to explain all differences between APOE4-negative and -positive AD patients, since most differences remained after adjusting the models for WML load. If anything, APOE4negative AD had even higher CSF A and tau levels when adjusting for WML ( Supplementary Figure 2) . One reason for this may be that WML is associated with lower CSF A concentrations 42 , so when adjusting for WML the CSF biomarker concentrations may become adjusted upwards.
Our results are in line with previous studies of APOE4, although those studies have focused on early onset AD 43 , or rare AD variants 35 . The pathogenic mechanism that drives the alternative AD phenotype in APOE4-negative patients remains unclear. The fact that APOE4-negative and -positive prodromal AD patients had similar 18 F-flutemetamol uptake supports the diagnosis of AD in both groups 44 , and suggest that the differences associated with APOE4 were not caused by differences in brain fibrillar A accumulation. Previous studies have been diverging, showing either no effects of APOE4 on A pathology in AD 45 , less A pathology in APOE4-positive AD 6,46 , or greater A pathology in APOE4-positive AD 47 . We propose that patients who develop A-pathology and clinical stages of AD despite lacking APOE4 may have other risk factors. These may be associated with greater atrophy, more aggressive neurodegeneration and more extensive white matter pathology, leading to a more dysexecutive cognitive profile. It is also possible that APOE4-positive people have A-independent effects on metabolism 48 and brain structure 49 , which influences the disease phenotype independent of A-pathology.
All main results pointed to more a deleterious phenotype in APOE4-negative prodromal AD. We believe that the consistency of these findings makes it very unlikely that they were falsely positive. We therefore report p-values uncorrected for multiple comparisons.
In summary, we found that APOE4-negative AD patients had an atypical phenotype with executive dysfunction, more rapid cognitive decline, increased brain atrophy, more white matter damage, and higher CSF concentrations of A peptides and markers of axonal injury.
The results emphasize the heterogeneity in AD and the need for molecular diagnostics of the disease. Hypothetically, APOE4-dependent differences in brain changes may influence effects of disease-modifying therapies in AD.
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